Kronos Bio

KRONOS BIO INC

Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

$1.9 Billion in Pre-Tax Charges for Job Cuts

Equities

News

Management

Markets

Movers

General

KRON

Kronos Bio announces major leadership changes and an 83% workforce reduction as part of a strategic overhaul, with stock gaining in premarket.

Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

Darwin Financial&#39;s Joshua Robinson talks to Benzinga about the firm&#39;s latest commodities deal, and more M&amp;A news from this past week.

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga&#39;s Deal Dispatch has the latest M&amp;A updates.

Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul

Kronos Bio Inc

Krones AG

KRONOS ADVANCED TECHS INC by Kronos Advanced Technologies, Inc.

Kronos Advanced Technologies Inc

Kronos Worldwide Inc

Press Releases

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Health Care

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Earnings

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

bluebird bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CytomX Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MAIA Biotechnology

Metagenomi

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

PMV Pharma

Serina Therapeutics

Skye Bioscience

Sutro Biopharma

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Piper Sandler

HC Wainwright & Co.

Goldman Sachs

Berenberg

Kronos

Comments

Kronos Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga